Literature DB >> 22123698

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

George Sakoulas1, Arnold S Bayer, Joseph Pogliano, Brian T Tsuji, Soo-Jin Yang, Nagendra N Mishra, Victor Nizet, Michael R Yeaman, Pamela A Moise.   

Abstract

We studied an ampicillin- and vancomycin-resistant Enterococcus faecium (VRE) isolate from a patient with endocarditis and bacteremia refractory to treatment with daptomycin (6 mg/kg of body weight) plus linezolid. Blood cultures cleared within 24 h of changing therapy to daptomycin (12 mg/kg) plus ampicillin. We examined the effects of ampicillin on daptomycin-induced growth inhibition and killing, surface charge, and susceptibility to several prototypical host defense cationic antimicrobial peptides. MICs and time-kill curves with daptomycin were assessed in the presence and absence of ampicillin. The impact of ampicillin on surface charge was assessed by flow cytometry and a poly-l-lysine binding assay. The effects of ampicillin preexposures upon VRE killing by five distinct cationic peptides of different structure, charge, origin, and mechanism of action were analyzed using the epidermal cathelicidin LL-37, thrombin-induced platelet microbicidal proteins (tPMPs), and a synthetic congener modeled after tPMP microbicidal domains (RP-1), human neutrophil peptide-1 (hNP-1), and polymyxin B (bacteria derived). Fluoroscein-Bodipy-labeled daptomycin was used to evaluate daptomycin binding to VRE membranes in the presence or absence of ampicillin. In media containing ampicillin (25 to 100 mg/liter), daptomycin MICs decreased from 1.0 to 0.38 mg/liter. Based on time-kill analysis and an in vitro pharmacodynamic model, ampicillin enhanced daptomycin activity against the study VRE from a bacteriostatic to a bactericidal profile. VRE grown in ampicillin (25 to 150 mg/liter) demonstrated an incremental reduction in its relative net positive surface charge. When grown in the presence (versus absence) of ampicillin (25 and 100 mg/liter), the VRE strain (i) was more susceptible to killing by LL-37, tPMPs, hNP-1, and RP-1 but not to polymyxin B and (ii) exhibited greater binding to Bodipy-labeled daptomycin. We conclude that ampicillin induces reductions in net positive bacterial surface charge of VRE, correlating with enhanced bactericidal effects of cationic calcium-daptomycin and a diverse range of other cationic peptides in vitro. While the mechanism(s) of such β-lactam-mediated shifts in surface charge remains to be defined, these finding suggest a potential for β-lactam-mediated enhancement of activity of both daptomycin and innate host defense peptides against antibiotic-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123698      PMCID: PMC3264218          DOI: 10.1128/AAC.05551-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 2.  Vancomycin resistance in gram-positive cocci.

Authors:  Patrice Courvalin
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

3.  Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  David Hirschwerk; Christine C Ginocchio; Maureen Bythrow; Susan Condon
Journal:  Infect Control Hosp Epidemiol       Date:  2006-02-23       Impact factor: 3.254

4.  Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.

Authors:  Holenarasipur R Vikram; Nancy L Havill; Laura M Koeth; John M Boyce
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci.

Authors:  F Cilli; S Aydemir; A Tunger
Journal:  J Chemother       Date:  2006-02       Impact factor: 1.714

7.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

8.  Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.

Authors:  Daniel J Skiest
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Authors:  Francisco M Marty; Wendy W Yeh; Christine B Wennersten; Lata Venkataraman; Esperanza Albano; Edwin P Alyea; Howard S Gold; Lindsey R Baden; Satish K Pillai
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

10.  Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus.

Authors:  Yan Q Xiong; Kasturi Mukhopadhyay; Michael R Yeaman; Jill Adler-Moore; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

View more
  77 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

Review 3.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

Review 4.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

5.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Authors:  Samira Dahesh; Brian Wong; Victor Nizet; George Sakoulas; Truc T Tran; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Antibiotics and Staphylococcus aureus--more than meets the MIC.

Authors:  Benjamin P Howden
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

8.  Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.

Authors:  Nader Mroue; Anu Arya; Autumn Brown Gandt; Cameron Russell; Angel Han; Ekaterina Gavrish; Michael LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 9.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.